Patents by Inventor Zenta Tsuchihashi
Zenta Tsuchihashi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11708610Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with cardiovascular disorders, particularly acute coronary events such as myocardial infarction and stroke, and genetic polymorphisms that are associated with responsiveness of an individual to treatment of cardiovascular disorders with statin. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.Type: GrantFiled: February 26, 2021Date of Patent: July 25, 2023Assignee: Celera CorporationInventors: Olga Iakoubova, James J. Devlin, Zenta Tsuchihashi, Peter Shaw, Lynn Marie Ploughman, Kim E. Zerba, Koustubh Ranade, Todd Kirchgessner
-
Publication number: 20210332434Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with cardiovascular disorders, particularly acute coronary events such as myocardial infarction and stroke, and genetic polymorphisms that are associated with responsiveness of an individual to treatment of cardiovascular disorders with statin. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.Type: ApplicationFiled: February 26, 2021Publication date: October 28, 2021Inventors: Michele CARGILL, Olga IAKOUBOVA, James J. DEVLIN, Zenta TSUCHIHASHI, Peter SHAW, Lynn Marie PLOUGHMAN, Kim E. ZERBA, Koustubh RANADE, Todd KIRCHGESSNER
-
Patent number: 10982281Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with cardiovascular disorders, particularly acute coronary events such as myocardial infarction and stroke, and genetic polymorphisms that are associated with responsiveness of an individual to treatment of cardiovascular disorders with statin. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.Type: GrantFiled: February 12, 2018Date of Patent: April 20, 2021Assignee: Celera CorporationInventors: Olga Iakoubova, James J. Devlin, Zenta Tsuchihashi, Peter Shaw, Lynn Marie Ploughman, Kim E. Zerba, Koustubh Ranade, Todd Kirchgessner
-
Publication number: 20180305762Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with cardiovascular disorders, particularly acute coronary events such as myocardial infarction and stroke, and genetic polymorphisms that are associated with responsiveness of an individual to treatment of cardiovascular disorders with statin. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.Type: ApplicationFiled: February 12, 2018Publication date: October 25, 2018Inventors: Michele CARGILL, Olga IAKOUBOVA, James J. DEVLIN, Zenta TSUCHIHASHI, Peter SHAW, Lynn Marie PLOUGHMAN, Kim E. ZERBA, Koustubh RANADE, Todd KIRCHGESSNER
-
Patent number: 9932637Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with cardiovascular disorders, particularly acute coronary events such as myocardial infarction and stroke, and genetic polymorphisms that are associated with responsiveness of an individual to treatment of cardiovascular disorders with statin. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.Type: GrantFiled: May 31, 2016Date of Patent: April 3, 2018Assignee: Celera CorporationInventors: Olga Iakoubova, James J. Devlin, Zenta Tsuchihashi, Peter Shaw, Lynn Marie Ploughman, Kim E. Zerba, Koustubh Ranade, Todd Kirchgessner
-
Publication number: 20170029888Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with cardiovascular disorders, particularly acute coronary events such as myocardial infarction and stroke, and genetic polymorphisms that are associated with responsiveness of an individual to treatment of cardiovascular disorders with statin. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.Type: ApplicationFiled: May 31, 2016Publication date: February 2, 2017Inventors: Michele CARGILL, Olga IAKOUBOVA, James J. DEVLIN, Zenta TSUCHIHASHI, Peter SHAW, Lynn Marie PLOUGHMAN, Kim E. ZERBA, Koustubh RANADE, Todd KIRCHGESSNER
-
Publication number: 20140221484Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with cardiovascular disorders, particularly acute coronary events such as myocardial infarction and stroke, and genetic polymorphisms that are associated with responsiveness of an individual to treatment of cardiovascular disorders with statin. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.Type: ApplicationFiled: October 3, 2013Publication date: August 7, 2014Applicants: BRISTOL-MYERS SQUIBB COMPANY, CELERA CORPORATIONInventors: Michele CARGILL, Olga IAKOUBOVA, James J. DEVLIN, Zenta TSUCHIHASHI, Peter SHAW, Lynn Marie PLOUGHMAN, Kim E. ZERBA, Koustubh RANADE, Todd KIRCHGESSNER
-
Patent number: 8257927Abstract: The invention relates generally to the gene, and mutations thereto, that are responsible for the disease hereditary hemochromatosis (HH). More particularly, the invention relates to the identification, isolation, and cloning of the DNA sequence corresponding to the normal and mutant HH genes, as well as the characterization of their transcripts and gene products. The invention also related to methods and the like for screening for HH homozygotes and further relates to HH diagnosis, prenatal screening and diagnosis, and therapies of HH disease, including gene therapeutics, protein and antibody based therapeutics, and small molecule therapeutics.Type: GrantFiled: July 7, 2011Date of Patent: September 4, 2012Assignee: Bio-Rad Laboratories, Inc.Inventors: Winston J. Thomas, Dennis T. Drayna, John N. Feder, Andreas Gnirke, David Ruddy, Zenta Tsuchihashi, Roger K. Wolff
-
Publication number: 20110269122Abstract: The invention relates generally to the gene, and mutations thereto, that are responsible for the disease hereditary hemochromatosis (HH). More particularly, the invention relates to the identification, isolation, and cloning of the DNA sequence corresponding to the normal and mutant HH genes, as well as the characterization of their transcripts and gene products. The invention also related to methods and the like for screening for HH homozygotes and further relates to HH diagnosis, prenatal screening and diagnosis, and therapies of HH disease, including gene therapeutics, protein and antibody based therapeutics, and small molecule therapeutics.Type: ApplicationFiled: July 7, 2011Publication date: November 3, 2011Inventors: Winston J. Thomas, Dennis T. Drayna, John N. Feder, Andreas Gnirke, David Ruddy, Zenta Tsuchihashi, Roger K. Wolff
-
Patent number: 7998680Abstract: The invention relates generally to the gene, and mutations thereto, that are responsible for the disease hereditary hemochromatosis (HH). More particularly, the invention relates to the identification, isolation, and cloning of the DNA sequence corresponding to the normal and mutant HH genes, as well as the characterization of their transcripts and gene products. The invention also related to methods and the like for screening for HH homozygotes and further relates to HH diagnosis, prenatal screening and diagnosis, and therapies of HH disease, including gene therapeutics, protein and antibody based therapeutics, and small molecule therapeutics.Type: GrantFiled: February 19, 2009Date of Patent: August 16, 2011Assignee: Bio-Rad Laboratories, Inc.Inventors: Winston J. Thomas, Dennis T. Drayna, John N. Feder, Andreas Gnirke, David Ruddy, Zenta Tsuchihashi, Roger K. Wolff
-
Publication number: 20100204051Abstract: The invention relates generally to the gene, and mutations thereto, that are responsible for the disease hereditary hemochromatosis (HH). More particularly, the invention relates to the identification, isolation, and cloning of the DNA sequence corresponding to the normal and mutant HH genes, as well as the characterization of their transcripts and gene products. The invention also related to methods and the like for screening for HH homozygotes and further relates to HH diagnosis, prenatal screening and diagnosis, and therapies of HH disease, including gene therapeutics, protein and antibody based therapeutics, and small molecule therapeutics.Type: ApplicationFiled: February 19, 2009Publication date: August 12, 2010Inventors: Winston J. Thomas, Dennis T. Drayna, John N. Feder, Andreas Gnirke, David Ruddy, Zenta Tsuchihashi, Roger K. Wolff
-
Publication number: 20100190172Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with cardiovascular disorders, particularly acute coronary events such as myocardial infarction and stroke, and genetic polymorphisms that are associated with responsiveness of an individual to treatment of cardiovascular disorders with statin. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.Type: ApplicationFiled: January 6, 2010Publication date: July 29, 2010Applicant: CELERA CORPORATIONInventors: Michele CARGILL, Olga IAKOUBOVA, James J. DEVLIN, Zenta TSUCHIHASHI, Peter SHAW, Lynn Marie PLOUGHMAN, Kim E. ZERBA, Koustubh RANADE, Todd KIRCHGESSNER
-
Publication number: 20100099090Abstract: CTLA-4 biomarkers useful in a method for predicting the likelihood that a mammal that will respond therapeutically to a method of treating cancer comprising administering an CTLA-4 antagonist, wherein the method comprises (a) measuring in the mammal the level of at least one biomarker s, (b) exposing a biological sample from the mammal to the CTLA-4 antagonist, and (c) following the exposing of step (b), measuring in the biological sample the level of the at least one biomarker, wherein an increase in the level of the at least one biomarker measured in step (c) compared to the level of the at least one biomarker measured in step (a) indicates an increased likelihood that the mammal will respond therapeutically to the method of treating cancer.Type: ApplicationFiled: March 4, 2008Publication date: April 22, 2010Applicant: Bristol-Mayers Squibb CompanyInventors: Zenta Tsuchihashi, Beihong Hu, Maria Jure-Kunkel
-
Patent number: 7579169Abstract: The invention relates generally to the gene, and mutations thereto, that are responsible for the disease hereditary hemochromatosis (HH). More particularly, the invention relates to the identification, isolation, and cloning of the DNA sequence corresponding to the normal and mutant HH genes, as well as the characterization of their transcripts and gene products. The invention also related to methods and the like for screening for HH homozygotes and further relates to HH diagnosis, prenatal screening and diagnosis, and therapies of HH disease, including gene therapeutics, protein and antibody based therapeutics, and small molecule therapeutics.Type: GrantFiled: January 5, 2006Date of Patent: August 25, 2009Assignee: Bio-Rad Laboratories, Inc.Inventors: Winston J. Thomas, Dennis T. Drayna, John N. Feder, Andreas Gnirke, David Ruddy, Zenta Tsuchihashi, Roger K. Wolff
-
Patent number: 7374765Abstract: Methods and compositions are provided for the diagnosis and treatment of iron misregulation diseases, including HFE polypeptides, agonists, and antagonists, and transferrin receptor agonists and antagonists.Type: GrantFiled: October 1, 2004Date of Patent: May 20, 2008Assignee: Bio-Rad Laboratories, Inc.Inventors: John N. Feder, Randall C. Schatzman, Zenta Tsuchihashi
-
Publication number: 20070259373Abstract: The present invention describes a G-protein coupled receptor (GPCR) family member newly identified as being modified, e.g., phosphorylated, and associated with tyrosine phosphorylated activation complexes, following exposure of cells to smoke from tobacco burning substances, namely, cigarette smoke. This GPCR protein is RAI-3, which was first found to be phosphorylated in cells treated with cigarette smoke and to be associated with other proteins activated in cigarette smoke treated cells by virtue of the present invention. Because cigarette smoke is considered to be a major causative factor of chronic obstructive pulmonary disease (COPD) and disorders and conditions related thereto, the RAI-3 protein is newly provided as a cellular drug target for screening, discovering, and identifying modulators for the treatment and/or prevention of COPD and its related disorders and conditions, such as emphysema and chronic bronchitis. In accordance with the present invention RAI-3 modulators, e.g.Type: ApplicationFiled: May 31, 2007Publication date: November 8, 2007Inventors: Gena Whitney, Gregory Opiteck, Leah Garulacan, Chandra Ramanathan, Murray McKinnon, Kelly Bennett, Lauren Barber, Angela Cacace, Zenta Tsuchihashi, John Feder
-
Publication number: 20060177854Abstract: The invention relates generally to the gene, and mutations thereto, that are responsible for the disease hereditary hemochromatosis (HH). More particularly, the invention relates to the identification, isolation, and cloning of the DNA sequence corresponding to the normal and mutant HH genes, as well as the characterization of their transcripts and gene products. The invention also related to methods and the like for screening for HH homozygotes and further relates to HH diagnosis, prenatal screening and diagnosis, and therapies of HH disease, including gene therapeutics, protein and antibody based therapeutics, and small molecule therapeutics.Type: ApplicationFiled: January 5, 2006Publication date: August 10, 2006Inventors: Winston Thomas, Dennis Drayna, John Feder, Andreas Gnirke, David Ruddy, Zenta Tsuchihashi, Roger Wolff
-
Patent number: 7078513Abstract: The invention relates generally to the gene, and mutations thereto, that are responsible for the disease hereditary hemochromatosis (HH). More particularly, the invention relates to the identification, isolation, and cloning of the DNA sequence corresponding to the normal and mutant HH genes, as well as the characterization of their transcripts and gene products. The invention also related to methods and the like for screening for HH homozygotes and further relates to HH diagnosis, prenatal screening and diagnosis, and therapies of HH disease, including gene therapeutics, protein and antibody based therapeutics, and small molecule therapeutics.Type: GrantFiled: February 4, 2000Date of Patent: July 18, 2006Assignee: Bio-Rad Laboratories, Inc.Inventors: Winston J. Thomas, Dennis T. Drayna, John N. Feder, Andreas Gnirke, David Ruddy, Zenta Tsuchihashi, Roger K. Wolff
-
Patent number: 7067255Abstract: The invention relates generally to the gene, and mutations thereto, that are responsible for the disease hereditary hemochromatosis (HH). More particularly, the invention relates to the identification, isolation, and cloning of the DNA sequence corresponding to the normal and mutant HH genes, as well as the characterization of their transcripts and gene products. The invention also related to methods and the like for screening for HH homozygotes and further relates to HH diagnosis, prenatal screening and diagnosis, and therapies of HH disease, including gene therapeutics, protein and antibody based therapeutics, and small molecule therapeutics.Type: GrantFiled: May 2, 2002Date of Patent: June 27, 2006Assignee: Bio-Rad Laboratories, Inc.Inventors: Winston J. Thomas, Dennis T. Drayna, John N. Feder, Andreas Gnirke, David Ruddy, Zenta Tsuchihashi, Roger K. Wolff
-
Publication number: 20050272054Abstract: The present invention is based on the discovery of genetic polymorphisms that are associated with cardiovascular disorders, particularly acute coronary events such as myocardial infarction and stroke, and genetic polymorphisms that are associated with responsiveness of an individual to treatment of cardiovascular disorders with statin. In particular, the present invention relates to nucleic acid molecules containing the polymorphisms, variant proteins encoded by such nucleic acid molecules, reagents for detecting the polymorphic nucleic acid molecules and proteins, and methods of using the nucleic acid and proteins as well as methods of using reagents for their detection.Type: ApplicationFiled: November 24, 2004Publication date: December 8, 2005Applicant: APPLERA CORPORATIONInventors: Michele Cargill, Olga Iakoubova, James Devlin, Zenta Tsuchihashi, Peter Shaw, Lynn Ploughman, Kim Zerba, Koustubh Ranade, Todd Kirchgessner